I
IPHA
Innate Pharma Sa
2.260
+0.080+3.67%After Hours: 2.276 +0.016 +0.69%16:34 08/17 EDT
OPEN/PREV CLOSE2.240/2.090
TODAY RANGE2.200-2.300
VOL29.05K
MARKET CAP208.95M
52 WEEK RANGE1.170-2.710
AVG VOL (3M)151.56K
% TURNOVER0.03%
TURNOVER--
P/E (TTM)-3.4617
% RANGE4.78%
EPS(TTM)-0.6442
P/E(FORWARD)-9.8891
P/B-8.2046
BVPS-0.2718
DIVIDEND--
P/S63.90
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP205.46M
SHARES OUTSTANDING93.70M
NEXT EARNINGS--
FREE FLOAT92.14M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Benzinga·08/14 12:06
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga·08/12 17:05
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga·08/12 12:06
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Dow Jones·08/12 09:39
Innate Pharma Price Target Raised to $9.00/Share From $8.00 by BTIG
Dow Jones·08/12 09:39
Innate Pharma Is Maintained at Buy by BTIG
Benzinga·08/12 09:29
BTIG Maintains Buy on Innate Pharma, Raises Price Target to $9
TipRanks·08/11 10:20
Leerink upgrades Innate Pharma to Outperform after lacutamab deal
TipRanks·08/11 10:15
Innate Pharma upgraded to Outperform from Market Perform at Leerink
Dow Jones·08/10 18:14
Innate Pharma Is Maintained at Buy by HC Wainwright & Co.
Dow Jones·08/10 18:14
Innate Pharma Price Target Raised to $7.00/Share From $5.00 by HC Wainwright & Co.
Benzinga·08/10 18:04
HC Wainwright & Co. Maintains Buy on Innate Pharma, Raises Price Target to $7
Benzinga·08/10 17:06
12 Health Care Stocks Moving In Monday's Intraday Session
TipRanks·08/10 16:30
Innate Pharma price target raised to $7 from $5 at H.C. Wainwright
Benzinga·08/10 14:03
Innate Pharma Jumps as Sobi Deal Boosts Secured Financing for Advancing Rare Skin Cancer Therapy
Same Industry
Name/Symbol
Change%
Price